ALK and non-small cell lung carcinoma: Platinum-based chemotherapy has been recommended as the standard of care for the first-line treatment of metastatic NSCLC patients with epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) wild-type in China (7).